🚀 VC round data is live in beta, check it out!
Devyser Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Devyser Diagnostics and similar public comparables like Airdoc, TeraView Holdings, Detection Technology, EKF Diagnostics and more.
Devyser Diagnostics Overview
About Devyser Diagnostics
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
Founded
2004
HQ
Employees
121
Website
Financials (LTM)
EV
$153M
Devyser Diagnostics Financials
Devyser Diagnostics reported last 12-month revenue of $30M and EBITDA of $5M.
In the same LTM period, Devyser Diagnostics generated $24M in gross profit, $5M in EBITDA, and $848K in net income.
Revenue (LTM)
Devyser Diagnostics P&L
In the most recent fiscal year, Devyser Diagnostics reported revenue of $28M and EBITDA of $3M.
Devyser Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $30M | XXX | $28M | XXX | XXX | XXX |
| Gross Profit | $24M | XXX | $22M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $5M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $848K | XXX | ($675K) | XXX | XXX | XXX |
| Net Margin | 3% | XXX | (2%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Devyser Diagnostics Stock Performance
Devyser Diagnostics has current market cap of $156M, and enterprise value of $153M.
Market Cap Evolution
Devyser Diagnostics' stock price is $9.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $156M | 0.3% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDevyser Diagnostics Valuation Multiples
Devyser Diagnostics trades at 5.2x EV/Revenue multiple, and 34.0x EV/EBITDA.
EV / Revenue (LTM)
Devyser Diagnostics Financial Valuation Multiples
As of April 19, 2026, Devyser Diagnostics has market cap of $156M and EV of $153M.
Equity research analysts estimate Devyser Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Devyser Diagnostics has a P/E ratio of 184.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $156M | XXX | $156M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 34.0x | XXX | 51.1x | XXX | XXX | XXX |
| EV/EBIT | 68.8x | XXX | 122.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | 7.0x | XXX | XXX | XXX |
| P/E | 184.3x | XXX | (231.6x) | XXX | XXX | XXX |
| EV/FCF | (20.2x) | XXX | (22.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Devyser Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Devyser Diagnostics Margins & Growth Rates
Devyser Diagnostics' revenue in the last 12 month grew by 20%.
Devyser Diagnostics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Devyser Diagnostics' rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Devyser Diagnostics' rule of X is 82% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Devyser Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 127% | XXX | 189% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Devyser Diagnostics Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Devyser Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Airdoc | XXX | XXX | XXX | XXX | XXX | XXX |
| TeraView Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Detection Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| EKF Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vuno | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Devyser Diagnostics M&A Activity
Devyser Diagnostics acquired XXX companies to date.
Last acquisition by Devyser Diagnostics was on XXXXXXXX, XXXXX. Devyser Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Devyser Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDevyser Diagnostics Investment Activity
Devyser Diagnostics invested in XXX companies to date.
Devyser Diagnostics made its latest investment on XXXXXXXX, XXXXX. Devyser Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Devyser Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Devyser Diagnostics
| When was Devyser Diagnostics founded? | Devyser Diagnostics was founded in 2004. |
| Where is Devyser Diagnostics headquartered? | Devyser Diagnostics is headquartered in Sweden. |
| How many employees does Devyser Diagnostics have? | As of today, Devyser Diagnostics has over 121 employees. |
| Is Devyser Diagnostics publicly listed? | Yes, Devyser Diagnostics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Devyser Diagnostics? | Devyser Diagnostics trades under DVYSR ticker. |
| When did Devyser Diagnostics go public? | Devyser Diagnostics went public in 2021. |
| Who are competitors of Devyser Diagnostics? | Devyser Diagnostics main competitors are Airdoc, TeraView Holdings, Detection Technology, EKF Diagnostics. |
| What is the current market cap of Devyser Diagnostics? | Devyser Diagnostics' current market cap is $156M. |
| What is the current revenue of Devyser Diagnostics? | Devyser Diagnostics' last 12 months revenue is $30M. |
| What is the current revenue growth of Devyser Diagnostics? | Devyser Diagnostics revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Devyser Diagnostics? | Current revenue multiple of Devyser Diagnostics is 5.2x. |
| Is Devyser Diagnostics profitable? | Yes, Devyser Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Devyser Diagnostics? | Devyser Diagnostics' last 12 months EBITDA is $5M. |
| What is Devyser Diagnostics' EBITDA margin? | Devyser Diagnostics' last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Devyser Diagnostics? | Current EBITDA multiple of Devyser Diagnostics is 34.0x. |
| What is the current FCF of Devyser Diagnostics? | Devyser Diagnostics' last 12 months FCF is ($8M). |
| What is Devyser Diagnostics' FCF margin? | Devyser Diagnostics' last 12 months FCF margin is (26%). |
| What is the current EV/FCF multiple of Devyser Diagnostics? | Current FCF multiple of Devyser Diagnostics is (20.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.